UBS Oncology Impact Fund L.P.

Insider Reports History

Location
Boston, MA
Signature
/s/ Ansbert Gadicke, managing partner of BioImpact LLC, the general partner of Oncology Impact Fund (Cayman) Management L.P., the GP of UBS Oncology Impact Fund L.P.
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by UBS Oncology Impact Fund L.P.:

Company Role Class Num Shares Value Price $ Report Date Ownership
Cullinan Oncology, Inc. 10%+ Owner Common Stock 7,648,268 $95,297,419 $12.46 16 Sep 2021 Direct
TCR2 THERAPEUTICS INC. 10%+ Owner Common Stock 0 $1.72 01 Jun 2023 Direct

Insider Reports Filed by UBS Oncology Impact Fund L.P.

Symbol Company Period Transactions Value $ Form Type Role Filing Time
/report/000120919123034346-ubs-oncology-impact-fund-l-p-2023-06-01 TCR2 THERAPEUTICS INC. 01 Jun 2023 1 $0 4 10%+ Owner 05 Jun 2023, 16:37
CGEM Cullinan Oncology, Inc. 16 Sep 2021 1 -$90,783 4 10%+ Owner 20 Sep 2021, 17:31
CGEM Cullinan Oncology, Inc. 14 Sep 2021 2 -$394,635 4 10%+ Owner 16 Sep 2021, 16:45
CGEM Cullinan Oncology, Inc. 09 Sep 2021 3 -$679,738 4 10%+ Owner 13 Sep 2021, 18:24
CGEM Cullinan Oncology, Inc. 03 Sep 2021 3 -$1,420,394 4 10%+ Owner 08 Sep 2021, 18:20
CGEM Cullinan Oncology, Inc. 31 Aug 2021 4 -$717,218 4 10%+ Owner 02 Sep 2021, 17:26
CGEM Cullinan Oncology, Inc. 23 Aug 2021 2 -$1,296,884 4 10%+ Owner 31 Aug 2021, 16:47
CGEM Cullinan Oncology, Inc. 23 Aug 2021 3 -$3,101,344 4 10%+ Owner 25 Aug 2021, 19:42
CGEM Cullinan Oncology, Inc. 11 Aug 2021 1 -$72,916 4 10%+ Owner 12 Aug 2021, 16:55